Last Published:  03/26/21 03:33:57 PM (Central)
Responsible Element: Human Health Countermeasures (HHC)
Status: Open
G-transition induced motion sickness represents one of the greatest clinical challenges impacting crew activities following G-transitions. Inflight incidence has varied with different spacecraft, with ~70% incidence and one-third reporting moderate to severe symptoms. The intensity and incidence of other perceptual and sensorimotor signs and symptoms generally follow this same pattern of intersubject variability. Inflight motion sickness has been reasonably treated by limiting early crew activities and the use of intramuscular promethazine. While there has limited severe cases of motion sickness following short-duration flights re-entry motion sickness become an even greater issue following long-duration missions.

Research approach: The risk needs to be characterized relative to the following critical mission tasks: G-transition motion sickness, diplopia, hand-eye coordination, autonomic dysfunction, vertigo.. Standardizing data collection across HRP Elements and cross-cutting projects will result in evidence-based standards that account for multiple contributing factors (e.g., changes in muscle strength, orthostatic intolerance and CNS due to radiation). Research should capture G-transition decrements and temporal recovery on mission relevant functional tasks. Research should focus on neural control of autonomic function, specifically vestibular pathways that may be compromised during and following G-transitions. Research should also focus on more subtle changes in vestibular (e.g., changes in asymmetry) and sensorimotor function (e.g., motor reflex and proprioception changes) as a function of mission duration. Research is also needed to address how partial gravity environments will impact risk, either by reducing the magnitude of the G-transition, or directly impacting performance through changes in physiologic demands (e.g., changes in thresholds).
Target for Closure
Define the magnitude of change and time course of recovery, and how these impact critical mission tasks (e.g., define the incidence of motion sickness following landing and how this impacts the crewmembers ability to accomplish critical tasks). Define how the risk (likelihood and severity) varies as a function of microgravity transit time, magnitude of G transition, and other contributing factors (prior experience, biomarkers, space radiation). Results/deliverables:  Understanding how G-transition alterations in neurovestibular function impacts the deconditioned crewmembers ability to perform critical operational tasks.
Risk Risk of Impaired Control of Spacecraft/Associated Systems and Decreased Mobility Due to Vestibular/Sensorimotor Alterations Associated with Spaceflight
You are here! Gap SM-103: Characterize the effects of short and long-duration weightlessness, with and without deep-space radiation, on spatial orientation and motion sickness after G transitions.

No Documentation Available